Bhagirathbhai Dholaria
Vanderbilt University/Ingram Cancer Center · Vanderbilt-Ingram Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bhagirathbhai Dholaria as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07763210 · Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaVanderbilt-Ingram Cancer Center · recruiting · Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma · principal investigator
- Ph2NCT07673367 · Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaVanderbilt-Ingram Cancer Center · recruiting · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator
- Ph2NCT02869633 · Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantVanderbilt-Ingram Cancer Center · completed · Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:57 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol · 2022234 citationsRCR 18.1
- Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Lancet Haematol · 2023157 citationsRCR 14.3
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Nat Med · 2023152 citationsRCR 13.2
- The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.Am J Hematol · 202061 citationsRCR 2.8
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Blood Cancer J · 202435 citationsRCR 4.3
- 28 citationsRCR 5.0
- Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.Blood · 202522 citationsRCR 6.4
- 22 citationsRCR 3.8
- 21 citationsRCR 3.7
- 14 citationsRCR 7.0